Bioventix reported a strong set of full-year results, that were 8% above expectations, assisted in part by a c.£0.2m (+3%) FX benefit, which helped offset the obvious drag on performance in Q4 due to the impact of COVID-19 on routine testing in hospitals. A 53p special dividend was proposed, resulting in a full-year dividend of 141p, up 18%. Due to the COVID-19-related disruption to testing, which only exacerbates the poor visibility to customer royalty streams, we are withdrawing forecasts unti ....
19 Oct 2020
Bioventix - FY 2020 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bioventix - FY 2020 results
Bioventix Plc (BVXP:LON) | 4,600 0 0.0% | Mkt Cap: 240.1m
- Published:
19 Oct 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
14
Bioventix reported a strong set of full-year results, that were 8% above expectations, assisted in part by a c.£0.2m (+3%) FX benefit, which helped offset the obvious drag on performance in Q4 due to the impact of COVID-19 on routine testing in hospitals. A 53p special dividend was proposed, resulting in a full-year dividend of 141p, up 18%. Due to the COVID-19-related disruption to testing, which only exacerbates the poor visibility to customer royalty streams, we are withdrawing forecasts unti ....